The Most Exciting Diabetes Technology Updates: Summer 2025 Edition

The American Diabetes Association’s 2025 Scientific Sessions in Chicago were full of fresh ideas and future-shaping diabetes technology breakthroughs, and Beyond Type 1 had a front-row seat.

Artificial Intelligence + Predictive Modeling

AI predicts type 1 diabetes 

• AI tools can detect early signs of type 1 diabetes up to a year before symptoms.
  • Earlier intervention prevents serious complications like diabetic ketoacidosis (DKA).
• Studies show AI tools outperforms current detection methods. 

GlyTwin 

• GlyTwin helps people with type 1 diabetes (T1D) avoid blood sugar spikes. 
• Offers tailored insulin/food advice to discover what works best for each person.
• GlyTwin worked better than other tools to stop highs, making diabetes care easier and safer.

Patch Pumps & the Future of Diabetes Technology

These innovations represent the cutting edge of diabetes technology, offering more personalized and user-friendly insulin delivery options.

Medtronic’s Patch Pump: MiniMed Fit

Medtronic unveiled the MiniMed Fit, a patch (i.e. on body, no tubing) insulin pump still in development.

• 300-unit insulin capacity with 7-day wear time.
• Semi-durable design: combines a rechargeable battery with a disposable component.
• Dual batteries provided, each lasting more than a week per charge.
• No launch date yet, but analysts don’t expect U.S. availability before 2027.

MiniMed Flex (8-Series) Tubed Pump

Also showcased was the MiniMed Flex, a next-gen tubed pump:

• Half the size of the current 780G model.
• No screen—controlled entirely via smartphone.
• 300-unit reservoir and 7-day wear.
• Compatible with both Medtronic’s Simplera Sync continuous glucose monitor (CGM) and Abbott’s Libre sensors.
• Expected to be submitted for FDA clearance by April 2026.

Beta Bionics’ Mint

• Beta Bionics unveiled Mint, a tubeless, phone-free insulin pump that doesn’t require charging.
• The semi-reusable pump lasts three days, holds 200 units of insulin and has the smallest cannula so far. 
• Mint could simplify diabetes care for those who prefer less tech.
• In development, without an announced release timeline.

Insulet’s Omnipod 5

• Omnipod 5 is now FDA-approved for people with type 2 diabetes.
• 30% of new Omnipod users in 2025 have type 2; they were prescribed the Omnipod 5 “off-label” (outside of FDA guidelines).
• Reduced stress in managing diabetes reported in Omnipod 5 users.
• Insulet is also working on new pumps to make insulin delivery even easier.

Tandem’s Sigi and Mobi

• Tandem is working on two new insulin patch pumps.
  • Rechargeable Sigi with prefilled cartridges.
  • Tubeless Mobi pump with app control.
• Both offer easier and more discreet insulin delivery. 
• In development, without an announced release timeline.

PharmaSens & SiBionics’ Niia Signature

• Niia Signature is a small patch pump that delivers insulin and checks glucose in one device. 
• The goal is to make diabetes care easier by replacing separate tools. 
• Niia Signature could help more people use automated insulin systems.
• In development, without an announced release timeline.

Beta Cell Therapy & Regeneration

Vertex’s zimislecel cell therapy 

• Zimislecel is an experimental treatment for T1D that uses lab-grown islet cells—specifically insulin-producing beta cells—derived from stem cells. 
  • Since T1D destroys these cells, patients rely on daily insulin.
• This one-time infusion provides new cells. In a study:
  • All 12 patients reached healthy blood sugar.
  • 10 no longer needed insulin after a year.
• The therapy may address T1D’s root cause, not just symptoms. 
• It’s still being tested and requires anti-rejection meds, but results so far are highly promising.

Sana Biotechnology’s UP421 

• Sana Biotechnology shared early results from its first human study of UP421, a new cell therapy for type 1 diabetes. 
• The treatment uses tiny lab-made beta cells that produce insulin and are specially designed to avoid being attacked by the immune system. 
• In early tests, the cells survived and made insulin without anti-rejection drugs—offering hope for fewer shots and more freedom in the future.

Sensor Innovation in Diabetes Technology

As diabetes technology evolves, sensors are becoming smarter, smaller, and more integrated into daily life.

Biolinq’s intradermal sensor 

• Biolinq’s new sensor monitors muscle loss due to GLP-1 therapy. 
• Small patch tracks muscle loss and protein intake through skin.
• Like a continuous glucose monitor (CGM) for muscle.

Glucotrack’s implantable CGM 

• This new sensor goes under your skin and lasts 3 years. 
• It checks sugar straight from your blood, not from interstitial fluid like regular CGMs.
• In trials, Glucotrack showed no safety issues and had a MARD of 7.7%. 
  • MARD (Mean Absolute Relative Difference) shows how close CGM readings are to lab results.
  • A lower MARD means better accuracy, and 7.7% matches today’s best CGMs
• Plus, Glucotrack is totally hidden. No gadgets stuck on your body!

GLP-1 Delivery & Personalization 

Vaxess Technologies’ patch 

• Vaxess delivers semaglutide (Ozempic, Wegovy, Rybelsus) without needles.
• In early tests, the patch worked and was safe. 
• Safe, fridge-free, and expands access—especially in underserved areas.

Remote Monitoring & Outcomes

Remote care is one of the fastest-growing areas in diabetes technology.

3-month remote CGM program 

• In a 3-month program, patients wore CGMs that tracked blood sugar 24/7. 
• Health care providers reviewed the data remotely, adjusted treatments, and gave personalized advice. 
• This hands-on support helped lower A1c from 10.4% to 7.5% and sped up foot wound healing—72% healed in 4 months vs. 47% without CGM.
• Even short-term use helped prevent serious complications, especially in underserved groups.

Emerging Diabetes Technology & Treatments on the Horizon

Endogenex’s ReCET System 

• New outpatient treatment for T2D. 
• Uses electric pulses to restore gut health. 
• Early research shows it may improve insulin use and beta-cell protection.

Abvance Therapeutics’ insulin-glucagon combo 

• May help prevent low blood sugar in T1D.
• Could offer a safer, more stable way to manage blood sugar during meals.